Johnson & Johnson's abiraterone acetate increases survival in prostate cancer trial

According to preliminary data from a late-stage trial presented at the European Society for Medical Oncology congress Monday, Johnson & Johnson's experimental drug abiraterone acetate, when combined with prednisone, increased median survival time of patients with advanced prostate cancer to 14.8 months, compared to 10.9 months for those who took the steroid alone. Last month, the drugmaker said that all patients participating in the study would be offered the drug after based on an interim analysis.
Reference Articles
Trial confirms prostate drug promise - (BBC News)
J&J drug for prostate cancer extends life in study - (Bloomberg)
New drug offers hope in advanced prostate cancer - (The Post Chronicle)
Prostate cancer drug a 'significant move forward' - (The Telegraph)
J&J prostate cancer drug prolongs survival - (TheStreet.com)
**Published in "First Word"